Copyright
©The Author(s) 2024.
World J Clin Cases. Jun 26, 2024; 12(18): 3360-3367
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3360
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3360
Table 3 Effect of cetuximab + FOLFOX4 regimen on safety in advanced gastric carcinoma patients receiving evidence-based care, n (%)
| Classification | Research group (n = 60) | Control group (n = 57) | χ2 | P value |
| Liver and kidney dysfunction | 0 (0.00) | 0 (0.00) | ||
| Leukopenia | 1 (1.67) | 1 (1.75) | ||
| Thrombocytopenia | 1 (1.67) | 2 (3.51) | ||
| Rash | 3 (5.00) | 3 (5.26) | ||
| Diarrhea | 1 (1.67) | 2 (3.51) | ||
| Total | 6 (10.00) | 8 (14.04) | 0.452 | 0.502 |
- Citation: Ying H, Huang RJ, Jing XM, Li Y, Tong QQ. Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care. World J Clin Cases 2024; 12(18): 3360-3367
- URL: https://www.wjgnet.com/2307-8960/full/v12/i18/3360.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i18.3360